The 12 most common account-based marketing mistakes and how to fix them for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install account-based marketing has to reflect that reality from day one.

Every account-based marketing failure we have investigated maps to one of the mistakes below. They repeat because they are structurally easy to make.

Mistake one, the foundational one: confusing ABM with lead scoring on inbound MQLs. Fix by naming an owner and writing kill criteria before you spend a dollar.

Mistake two: mistaking volume for progress. Fix by making pipeline created inside the named-account list the only weekly headline number.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Account-based marketing is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Mistake three: buying tools before defining the workflow. Fix by drawing the workflow on paper first and buying only what the paper shows.

Mistake four: shipping without a quality gate. Fix by requiring a human eyeball on every artefact for the first four weeks.

Mistake five: ignoring the trigger. Account-based marketing works when one enterprise close is worth six mid-market ones; without a real trigger the model is guesswork.

Mistake six through twelve: cascade from the first five. Fix the top five and most of the others resolve themselves inside a month.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing account-based marketing properly rather than half-heartedly across three vendors.